IONIS PHARMACEUTICAL

IONS
Delayed Quote. Delayed  - 09/27 04:00:00 pm
35.87USD -0.91%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 7 9065 063
Entreprise Value (EV)1 8 0475 186
P/E ratio -17,5x-19,5x
Yield --
Capitalization / Revenue 10,8x8,19x
EV / Revenue 11,0x8,39x
EV / EBITDA -50,7x-22,7x
Price to Book 9,39x7,84x
Nbr of stocks (in thousands) 139 823141 148
Reference price (USD) 56,535,9
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 729618
EBITDA1 -159-229
Operating profit (EBIT)1 -172-259
Operating Margin -23,6%-41,9%
Pre-Tax Profit (EBT)1 -170-254
Net income1 -451-258
Net margin -61,9%-41,7%
EPS2 -3,23-1,84
Dividend per Share2 --
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 141123
Net Cash position1 --
Leverage (Debt / EBITDA) -0,89x-0,54x
Free Cash Flow1 772-52,6
ROE (Net Profit / Equities) -3,88%-31,7%
Shareholders' equity1 11 634813
ROA (Net Profit / Asset) -4,40%-10,6%
Assets1 10 2452 438
Book Value Per Share2 6,024,57
Cash Flow per Share2 0,26-0,56
Capex1 35,126,3
Capex / Sales 4,82%4,25%
Announcement Date 02/24/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 5 063 M $ -
Entreprise Value (EV) 5 186 M $ 5 290 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -19,5x -19,2x
Capitalization / Revenue 8,19x 7,83x
EV / Revenue 8,39x 8,02x
EV / EBITDA -22,7x -29,9x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 7,84x 19,2x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -41,9% -40,6%
Operating Leverage (Delta EBIT / Delta Sales) -3,33x -
Net Margin (Net Profit / Revenue) -41,7% -38,3%
ROA (Net Profit / Asset) -10,6% -12,1%
ROE (Net Profit / Equities) -31,7% -44,6%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,25% 4,19%
Cash Flow / Sales -12,7% -11,2%
Capital Intensity (Assets / Sales) 3,94x 3,17x
Financial Leverage (Net Debt / EBITDA) -0,54x -1,31x
EPS & Dividend